TherapeuticsMD Announces Second Quarter 2019 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/2/2026
- S&P 500, Dow rise as AI boost counters US-Iran tensions
- Oil rises, as US-Iran strikes risk limiting already impaired supplies
- Dell again lifts annual forecasts as AI demand powers record results
- Could Apple’s foldable iPhone be a $14B opportunity? Morgan Stanley weighs in
- Uber stock gains 2% as tech giant cuts 3,300 jobs in major restructuring
- GoPro to merge with Starman Optical in $285M recapitalization deal
- GoPro (GPRO) Halted, News Pending
- Wall Street ends lower as higher yields, rising oil prices mark shaky start to September
- Google defeats US bid to force ad tech sale
- Gap taps Coach architect Reed Krakoff for $29.95-$498 handbag line
TherapeuticsMD (TXMD) Misses Q2 EPS by 6c, Revenues Beat; Raises Q3 & FY19 Revenue Guidance
August 6, 2019 5:21 PM EDTTherapeuticsMD (NASDAQ: TXMD) reported Q2 EPS of ($0.23), $0.06 worse than the analyst estimate of ($0.17). Revenue for the quarter came in at $6 million versus the consensus estimate of $5.12 million.
MVEXXY® Net Revenue $3.1 Million for the Second Quarter of 2019Total Net Revenue for the Second Quarter of 2019 Above... More